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Abstract Single-photon emission computed tomography
(SPECT) and position emission tomography (PET) are the
two main imaging modalities in nuclear medicine. SPECT
imaging is more widely available than PET imaging and the
radionuclides used for SPECT are easier to prepare and
usually have a longer half-life than those used for PET. In
addition, SPECT is a less expensive technique than PET.
Commonly used gamma emitters are:
99mTc (Emax 141 keV,
T1/2 6.02 h),
123I( E max 529 keV, T1/2 13.0 h) and
111In
(Emax 245 keV, T1/2 67.2 h). Compared to clinical SPECT,
PET has a higher spatial resolution and the possibility to
more accurately estimate the in vivo concentration of a
tracer. In preclinical imaging, the situation is quite different.
The resolution of microSPECT cameras (<0.5 mm) is
higher than that of microPET cameras (>1.5 mm). In this
report, studies on new radiolabelled tracers for SPECT
imaging of angiogenesis in tumours are reviewed.
Keywords Angiogenesis.αvβ3.VEGF.PMSA.ECM
Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing vasculature, is one of the key requirements if solid
tumours are to grow beyond 2–3m m
3, since diffusion is no
longer sufficient to supply the tissue with oxygen and
nutrients [1]. Tumour-induced angiogenesis is a complex
multistep process that follows a characteristic cascade of
events mediated and controlled by growth factors, cellular
receptors and adhesion molecules [2–4]. In this process,
five phases can be distinguished: (1) endothelial cell
activation, (2) basement membrane degradation, (3) endo-
thelial cell migration, (4) vessel formation and (5) angio-
genic remodelling [5].
The activation of pre-existing quiescent vessels can be
triggered by hypoxia. Hypoxia induces the expression of
hypoxia-inducible factor (HIF), which binds to the hypoxic
response element. As a result, the expression of hypoxia-
inducible genes, such as vascular endothelial growth factor
(VEGF), carbonic anhydrase IX (CAIX), platelet-derived
growth factor (PDGF) and transforming growth factor-α
(TGF-α), is induced [6].
Activated endothelial cells express the dimeric trans-
membrane integrin αvβ3, which interacts with extracellular
matrix proteins (vitronectin, tenascin, fibronectin, a.o.) and
regulates migration of the endothelial cell through the
extracellular matrix during vessel formation [7, 8]. The
activated endothelial cells synthesize proteolytic enzymes,
such as matrix metalloproteinases (MMPs), used to degrade
the basement membrane and the extracellular matrix [9].
Initially, endothelial cells assemble as solid cords. Subse-
quently, the inner layer of endothelial cells undergoes
apoptosis leading to the formation of the vessel lumen.
Finally this primary, immature vasculature undergoes
extensive remodelling during which the vessels are stabi-
lized by pericytes and smooth muscle cells. This step is
often incomplete in tumours resulting in the characteristic,
increased permeability of tumour vessels.
Based on a balance between proangiogenic and anti-
angiogenic factors, a tumour can stay dormant for a very
long time period until the so-called angiogenic switch
occurs. In most tissues tumours can only grow to a life-
threatening size if the tumour is able to trigger angiogen-
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a.o.), tumours may also progress via angiogenesis-
independent co-option of the pre-existent vasculature [10].
In summary, tumour-induced angiogenesis is a multistep
process and a key feature of a tumour lesion that has major
impact on the biological behaviour of the lesion. Inhibition
of angiogenesis is a new cancer treatment strategy that is
now being widely investigated clinically. Researchers have
begun to search for objective measures that indicate
pharmacological responses to antiangiogenic drugs. There-
fore, there is great interest in techniques to visualize
angiogenesis in growing tumours non-invasively. During
the past decade several markers of angiogenesis have been
identified and specific tracers targeting these markers have
been developed.
VEGF receptors
VEGF is a key regulator of angiogenesis during embryo-
genesis, skeletal growth and reproductive functions. The
expression of VEGF is upregulated by environmental stress
caused by hypoxia, anaemia, myocardial ischaemia and
tumour progression to initiate neovascularization [11]. Via
alternative mRNA splicing, the human VEGF-A gene gives
rise to four isoforms having 121, 165, 189 and 206 amino
acids (VEGF121, VEGF165, VEGF189 and VEGF206, re-
spectively) [12, 13]. Less frequent splice variants have been
identified more recently, including VEGF145 [14], VEGF183
[15], VEGF162 [16] and VEGF165b [17]. The VEGF
isoforms differ not only in their molecular mass, but also
in their solubility and receptor-binding characteristics.
Initially, VEGF receptors were identified on the cell
surface of vascular endothelial cells in vitro [18, 19] and in
vivo [20, 21]. Subsequently, it was demonstrated that
receptors for VEGF also are expressed on bone marrow-
derived cells such as monocytes [22]. VEGF-A binds two
related receptor tyrosine kinases (RTKs), VEGFR-1 and
VEGFR-2. Both receptors consist of seven Ig-like domains
in the extracellular domain, a single transmembrane region
and a consensus tyrosine kinase sequence that is interrupted
by a kinase insert domain [23–25]. VEGFR-1 binds VEGF
with a higher affinity compared to VEGFR-2 (Kd:2 5v s
75–250 pM) [26–28]. VEGFR-1 is considered to be a
decoy receptor and VEGF-A only signals through VEGFR-
2[ 29].
SPECT imaging of VEGF receptors
Two VEGF isoforms, VEGF121 and VEGF165, have been
investigated for their potential to visualize VEGFR expres-
sion by SPECT. VEGF121 and VEGF165 were radioiodi-
nated with
123I and the binding properties of
123I-VEGF121
and
123I-VEGF165 to human umbilical vein endothelial
cells, various human tumour cell lines and a variety of
primary human tumours were determined [30].These
studies showed that
123I-VEGF121 and
123I-VEGF165
specifically bound to various tumour cell types. In
comparison with
123I-VEGF121,
123I-VEGF165 bound to a
higher number of different tumour cell types with a higher
capacity. In a subsequent preliminary clinical study,
123I-
VEGF165 appeared to be safe and
123I-VEGF165 visualized
gastrointestinal tumours and metastasis expressing VEGF
receptors [31]. Although CT/MRI was superior compared
to
123I-VEGF165 scintigraphy in a lesion-by-lesion compar-
ison, the authors concluded that
123I-VEGF165 might be
useful for visualization of tumour angiogenesis.
In another clinical study, the biodistribution, safety and
absorbed dose of
123I-VEGF165 in patients with pancreatic
carcinoma were investigated [32]. A majority of primary
pancreatic tumours and their metastases were visualized at
3 h after
123I-VEGF165 administration.
In order to develop non-invasive, specific techniques to
estimate tumour vascularity, Yoshimoto and co-workers
evaluated
125I-VEGF121 and
125I-VEGF165 as angiogenesis
imaging agents in mice with LS180 tumours [33].
125I-
VEGF121 displayed significantly higher tumour uptake and
higher tumour to non-tumour (T/N) ratios as compared to
125I-VEGF165. The tumour accumulation of
125I-VEGF121
decreased with increasing tumour volume. However, in this
study it was not investigated whether the uptake of
125I-
VEGF121 and
125I-VEGF165 in the tumour and other organs
and tissues was VEGF receptor-mediated.
Besides radioiodinated VEGF-based isoforms, also
VEGF-based isoforms labelled with radiometals such as
99mTc and
111In have been investigated. Blankenberg and
co-workers described a novel imaging complex comprised
of a standardized
99mTc-radiolabelled adapter protein non-
covalently bound to a “docking tag” fused to a “targeting
protein”. The assembly of this complex was based on
interactions between human 109-amino acid (HuS) and 15-
amino acid (Hu-tag) fragments of ribonuclease I, which
served asan “adapter protein” and a docking tag, respectively.
The resulting
99mTc-HuS/Hu-VEGF complex could be
effectively used to image the murine tumour neovasculature
in lesions as small as a few millimetres in soft tissue in mice
with 4T1-luc tumours [34]. In the same animal model, the
HYNIC-conjugated
99mTc-HYNIC-VEGF had a similar
biodistribution as the
99mTc-HuS/Hu-VEGF complex.
SPECT imaging using
99mTc-HYNIC-VEGF showed highly
heterogeneous focal accumulation in the tumour area.
SPECT imaging with
99mTc-HYNIC-VEGF could also
readily detect the effects of chemotherapeutic treatment of
4T1 tumours [35]. Binding specificity was confirmed by the
75% decrease in tumour uptake of
99mTc-biotin-inactivated
VEGF, as compared to
99mTc-HYNIC-VEGF.
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composed of VEGF165 fused through a flexible polypeptide
linker (GGGGS)3 to the n-lobe of human transferrin (hnTf)
for imaging angiogenesis [36]. The VEGF construct was
conjugated to the n-lobe of hnTf to allow labelling with
111In
at a site remote from the VEGF receptor-binding domain.
111In-hnTf-VEGF accumulated in U87MG glioblastoma
xenografts [6.7%ID/g, 72 h post-injection (p.i.)] in athymic
mice and its tumour uptake decreased 15-fold by coadmin-
istration of a 100-fold excess VEGF, indicating that the
tracer specifically accumulated in U87MG tumours.
The studies described above were all done with VEGF
isoforms. Alternatively, studies with radiolabelled anti-
VEGF antibodies and derivatives thereof have also been
reported. Bevacizumab is a humanized variant of the anti-
VEGF-A monoclonal antibody (mAb) A.4.6.1. It is directed
against a common epitope encoded by exon 4, present on
all VEGF isoforms, and prevents interaction of VEGF with
VEGFR-1 and VEGFR-2 [37]. Nagengast et al. were the
first to demonstrate non-invasive VEGF imaging using
radiolabelled bevacizumab. In their study, they demonstrat-
ed the potential of
89Zr-bevacizumab and
111In-bevacizu-
mab as a specific VEGF tracer in nude mice with human
SKOV-3 ovarian tumour xenografts [38]. At the same time,
our group showed specific imaging of VEGF-A expression
using
111In-bevacizumab in mice with s.c. human colon
carcinoma xenografts LS174T [39]. We were the first to
investigate the potential of
111In-labelled bevacizumab to
image the expression of VEGF-A in tumours in cancer
patients. In a study in colorectal cancer patients with liver
metastases, the liver metastases in 9 of 12 patients were
visualized with
111In-bevacizumab (Fig. 1). In this study,
the liver metastases were resected after scintigraphic
imaging allowing further immunohistochemical analysis.
The VEGF-A expression in these resected liver metastases
was determined by in situ hybridization and by measuring
VEGF in tumour extracts by enzyme-linked immunosor-
bent assay (ELISA). Surprisingly, no correlation was found
between the level of antibody accumulation and the level of
VEGF-A expression.
In a preclinical study, the biodistribution of
111In-
labelled bevacizumab and
111In-labelled ranibizumab, an
anti-VEGF Fab fragment, were compared in nude mice
with SKOV-3 ovarian tumours. Although bevacizumab
showed the highest tumour uptake, ranibizumab allowed
imaging earlier after injection of the tracer, making the Fab
fragment tracer more suited to monitor rapid changes of
VEGF expression following therapy. SPECT imaging using
111In-labelled bevacizumab revealed tumour lesions in both
melanoma and metastatic colon cancer patients [40].
αvβ3 integrin receptor
The αvβ3 integrin, also referred to as the vitronectin
receptor, belongs to the integrin receptors. Integrins are a
family of heterodimeric transmembrane glycoproteins that
function in cellular adhesion, migration and signal trans-
duction. Each member of this family consists of two non-
covalently bound transmembrane polypeptide subunits,
alpha and beta.
Activated endothelial cells express the integrin αvβ3
receptor, whereas this integrin receptor is absent on
quiescent endothelial cells. In addition, αvβ3 is expressed
on the cell membrane of various tumour cell types such as:
ovarian cancer, neuroblastoma, breast cancer, melanoma,
a.o. αvβ3 Integrin expressed on endothelial cells modulates
cell migration and survival during angiogenesis, whereas
αvβ3 integrin expressed on carcinoma cells potentiates
metastasis by facilitating invasion and movement across
blood vessels. Due to this restricted expression of αvβ3 in
tumours, αvβ3 is considered a suitable target for imaging
angiogenesis [41]. Radiolabelled ligands for this integrin
can be used as tracers to non-invasively visualize αvβ3
expression in tumours. Non-invasive visualization of αvβ3
expression might provide information about the angiogenic
ab
Fig. 1 a Scintigraphic imaging of a liver metastasis with
111In-bevacizumab. b Four-phase CT scan: imaging of liver metastasis
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SPECT imaging of αvβ3 expression
Integrin αvβ3 binds extracellular matrix proteins (e.g.
vitronectin, fibrinogen, laminin, collagen) through exposed
tripeptide arginine-glycine-aspartic acid (RGD) amino acid
moieties [42]. Several research groups have investigated the
potential of RGD-containing peptides to target αvβ3
expressed in tumours with radionuclides. It was found that
the cyclic pentapeptide cyclo(Arg-Gly-Asp-D-Phe-Val),
having an IC50 value in the lower nanomolar range, was a
100-fold better inhibitor of cell adhesion to vitronectin
compared to the linear variant [43, 44]. It was found that
besides the essential RGD sequence, a hydrophobic amino
acid in position 4 increases the affinity for αvβ3 [45]. Based
on this finding Haubner and co-workers designed five
peptides that could be radioiodinated by introducing a
tyrosine residue. Two of these peptides, cyclo(Arg-Gly-
Asp-D-Tyr-Val) and cyclo(Arg-Gly-Asp-D-Phe-Tyr) (des-
ignated as P1 and P4, respectively) were studied in vivo
[46]. The biodistribution of the radioiodinated peptides was
studied in nude mice with various s.c. human tumours
(M21 melanoma, MaCaF mammary carcinoma and osteo-
sarcoma). The peptides rapidly cleared from the blood
(<1%ID/g at 10 min p.i.). In the M21 melanoma model, the
tumour uptake peaked at 10 min p.i. (1.12±0.98%ID/g) and
decreased to 0.12±0.04%ID/g at 2 h p.i. However, both
peptides cleared via the hepatobiliary route and revealed
relatively high hepatic uptake, especially at early time
points (∼5%ID/g, 1 h p.i.). Therefore, the pharmacokinetics
of these RGD peptides were improved by conjugating them
with sugar amino acids. A glucose-based sugar amino acid
(SAA1) was conjugated to the epsilon-amino function of
lysine in the pentapeptide. Compared to the non-carbohydrate
radioiodinated P4, the resulting iodine-labelled glycopeptide
3-[*I]iodo-D-Tyr4-cyclo(Arg-Gly-Asp-D-Tyr-Lys (SAA1))
(*I-gluco-RGD) showed reduced activity accumulation in
the liver, enhanced blood levels and increased uptake and
retention in the tumour [47]. Based on these data a galactose-
based sugar amino acid (SAA2) was conjugated with cyclo
(Arg-Gly-Asp-D-Phe-Lys) allowing prosthetic group label-
ling [47, 48].
van Hagen and co-workers conjugated a DTPA moiety
via the epsilon group of the lysine residue in the cyclic
pentapeptide cyclo(Arg-Gly-Asp-D-Tyr-Lys). The resulting
ligand could be radiolabelled with both
111In and radio-
iodine. The radiolabelled peptide bound specifically to
αvβ3-positive cells. DTPA conjugation made the peptide
more hydrophilic and facilitated renal clearance, in contrast
to the non-DTPA-conjugated radioiodinated peptide which
cleared predominantly via the hepatobiliary route [49].
An alternative lead structure compared to the head-to-tail
cyclized RGD-containing pentapeptide is the disulphide-
bridged RGD-4C (Cys
2-Cys
10, Cys
4-Cys
8) H-Ala-Cys-Asp-
Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-OH which binds with
high affinity to both αvβ3 and αvβ5 (KD ∼ 100 nM) [50].
Its derivative (Cys
1-Cys
9, Cys
3-Cys
7) H-Cys-Asp-Cys-Arg-
Gly-Asp-Cys-Phe-Cys-OH was conjugated with HYNIC
and subsequently radiolabelled with
99mTc. In in vivo
studies, this
99mTc-HYNIC-RGD had marginal tumour
uptake in mice with αvβ3-positive tumours [51, 52]. The
deletion of the terminal amino acids, the conjugation with
HYNIC and/or the labelling with
99mTc could have
impaired the affinity of the peptide for the receptor.
Clinical studies
Sivolapenko and colleagues were the first who investigated
the synthetic linear RGD analogue αP2 (Arg-Gly-Asp-Ser-
Cys-Arg-Gly-Asp-Ser-Tyr) to image tumour angiogenesis
in patients [53, 54]. Fourteen melanoma patients received
185–1222 MBq of the
99mTc-labelled peptide intravenously
(i.v.) and were imaged up to 3 h p.i. The peptide cleared
rapidly from the blood (T1/2α=5.5±2.2 min and T1/2β=
34.3±11.0 min) by filtration through the kidneys and
excretion in the urine (>90%ID in kidneys and bladder at
1 h p.i.). Of the 22 metastatic lesions in these patients, 17
were visualized.
The
99mTc-labelled RGD-containing peptide (NC100692,
Fig. 2) was evaluated in ischaemic models and showed high
uptake in areas of neovascularization with αvβ3 integrin
overexpression [55]. In these models it was shown that
NC100692 bound to αvβ3-expressing endothelial cells in
regions of angiogenesis [56].
Subsequently,
99mTc-NC100692 was tested in women with
histologically proven breast cancer.
99mTc-NC100692 detected
malignant breast tumours efficiently [57]. Of 20 malignant
tumours, 19 were detected and there were no safety concerns
related to the administration of
99mTc-NC100692 [58].
To determine the feasibility of detecting metastatic
lesions in liver, lung, bone and brain with scintigraphy,
99mTc-NC100692 was used in an open-label, multicentre,
phase 2a study in late-stage cancer patients [59]. Therefore,
25 patients, 15 with lung cancer and 10 with breast cancer,
were recruited at 10 centres. In patients with breast cancer,
99mTc-NC100692 scintigraphy detected 1 of 7 liver, 4 of 5
lung, 8 of 17 bone and 1 of 1 brain metastases. The
corresponding numbers in lung cancer patients were 0 of 2,
17 of 18, 2 of 2 and 7 of 9. Despite the low number of
patients with liver metastases included in this study, the
authors concluded that the sensitivity to detect liver metas-
tases was poor and the detection of bone metastases is
equivocal with
99mTc-NC100692. However, it was feasible to
detect lung and brain metastases from breast and lung cancer.
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To improve tumour targeting and to obtain better in vivo
imaging properties, several research groups aimed to
enhance the affinity toward the αvβ3 integrin by using
multimeric RGD peptides. Janssen et al. conjugated two
cyclo(RGDfK) peptides via a glutamic acid linker, conju-
gated it with HYNIC and radiolabelled it with
99mTc. The
dimeric
99mTc-HYNIC-E-[c(RGDfK)]2 showed a tenfold
higher affinity for αvβ3 and a better retention than the
monomeric
99mTc-HYNIC-E-c(RGDfK) [60]. However, the
dimer also had higher uptake in the kidneys. Possibly,
the presence of more guanidine groups in the dimer
caused the enhanced renal uptake [61].
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Fig. 2 a Structural formula of NC100692. b Patient with uptake of 99mTc-NC100692 in cancer in the left breast, axillary and subclavicular
lymf nodes (This image was kindly provided by Dr. Rimma Axelsson, Division of Radiology, Karolinska Institutet, Stockholm, Sweden)
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111In- and
99mTc-labelled dimeric RGD peptide derivatized
with the chelators DOTA or HYNIC, respectively, was
investigated in mice with s.c. NIH:OVCAR-3 tumours [62].
Tumour uptake peaked at 7.5%ID/g for
111In-DOTA-E-[c
(RGDfK)]2 (2 h p.i.) and 6.0%ID/g for
99mTc-HYNIC-E-[c
(RGDfK)]2 (1 h p.i.).
The multivalency effect was further explored by the
synthesis of the DOTA-conjugated tetrameric analogue E{E
[c(RGDfK)]2}2 [63]. The in vitro affinity and the in vivo
tumour targeting characteristics of the
111In-labelled mono-,
di- and tetramer to αvβ3-expressing tumours were deter-
mined (IC50 values; monomer: 120 nM, dimer: 69.9 nM
and tetramer: 19.6 nM). The tetramer showed improved
tumour targeting (7.40±1.12%ID/g) compared to the dimer
(5.17±1.22%ID/g at 8 h p.i.). Analogously, the dimer
demonstrated improved tumour targeting compared to the
monomer (2.30±0.34%ID/g at 8 h p.i., Fig. 3).
The application of dimers and tetramers as SPECT
radiotracers by tethering together c(RGDfK) units via a
glutamic acid tree has been studied extensively. Recently, a
variety of c(RGDfK) multimers assembled via the RAFT
template [64] or click chemistry [65] was studied as well. In
all of the multimeric RGD studies described above, it was
found that multimerization of cyclic RGD peptides en-
hanced their integrin αvβ3-binding affinity and improved
the tumour uptake of the radiotracer. However, the uptake
of the radiotracers in kidney and liver also increased
significantly as the peptide multiplicity increased. In
addition, the synthesis of the c(RGDxK)-based tetra- and
octamers (x=f or y) is much more complicated and could
limit their introduction into clinical practice.
In general, there are two main factors that contribute to a
higher αvβ3-binding affinity of multimeric RGD peptides
compared to their monomeric counterparts: (1) simulta-
neous αvβ3 integrin binding by two RGD motifs or (2) the
locally enriched RGD concentration. To achieve simulta-
neous integrin αvβ3 binding (=multivalency), the distance
between the RGD motifs in multimeric RGD peptides must
be long enough and flexible enough. There are some
disadvantages of using tetra- or octameric RGD peptides
over their dimeric counterparts, such as the more compli-
cated synthesis and higher uptake in non-target organs. To
solve these problems, pharmacokinetic modifier (PKM)
linkers between the two RGD motifs in dimeric RGD
peptides have been tested in several studies.
In an attempt to increase the affinity of E[c(RGDfK)]2,
Shi and co-workers developed a series of cyclic RGD
dimers containing triglycine (G3) and PEG4 linkers, which
were used to increase the distance between two cyclic RGD
units from 6 bonds in E[c(RGDfK)]2 to 24 bonds in 3G3-
dimer and 38 bonds in 3PEG4-dimer [66, 67]. In in vitro
binding studies on U87MG human glioma cells, the linker-
containing dimers HYNIC-3PEG4-dimer (IC50=60±4 nM)
and HYNIC-3G3-dimer (IC50=61±2 nM) had a higher
affinity than HYNIC-PEG4-dimer (IC50=84±7 nM), which
had a short linker between the RGD units. The HYNIC-
tetramer had a higher binding affinity (IC50=7±2 nM)
probably due to its two extra RGD units. In mice with s.c.
U87MG glioma and MDA-MB-435 breast tumour xeno-
grafts, the tumour uptake of
99mTc-HYNIC-3PEG4-dimer
and
99mTc-HYNIC-3G3-dimer was similar to that of the
99mTc-HYNIC-tetramer, indicating divalent binding of the
three tracers. The tumour uptake of the
99mTc-HYNIC-
PEG4-dimer was much lower, suggesting monovalent
binding. Furthermore,
99mTc-HYNIC-3PEG4-dimer and
99mTc-HYNIC-3G3-dimer had kidney and liver uptake that
w a sh a l fo ft h a to ft h e
99mTc-HYNIC-tetramer. In a
subsequent study,
111In-DOTA-3PEG4-dimer,
111In-DTPA-
3PEG4-dimer and
111In-DTPA-Bn-3PEG4-dimer were syn-
thesized and compared in in vitro and in vivo studies [68].
The affinities were 1.3±0.2, 1.4±0.3 and 1.3±0.3 nM,
respectively. In mice with s.c. U87MG glioma xenografts,
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Fig. 3 a Biodistribution of
111In-DOTA-E-c(RGDfK),
111In-DOTA-
E-[c(RGDfK)]2 and
111In-DOTA-E{E[c(RGDfK)]2}2 at 8 h p.i. in
athymic mice with s.c. SK-RC-52 tumours (5 mice/group). b Tumour
to blood ratios of
111In-DOTA-E-c(RGDfK),
111In-DOTA-E-[c
(RGDfK)]2 and
111In-DOTA-E{E[c(RGDfK)]2}2 at 2, 8 and 24 h
after injection in athymic mice with s.c. SK-RC-52 tumours. Each bar
represents the mean values ± SD. Values were analysed using one-way
analysis of variance, *p<0.05
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excellent tumour to background (T/B) ratios up to 4 h p.i.
After that time point, both DTPA-conjugated derivatives
showed a much faster tumour washout and poorer T/B
ratios than the DOTA-conjugated derivative.
So far, 3PEG4-dimer and 3G3-dimer seem suitable
candidates for SPECT imaging of angiogenesis in clinical
studies.
Extracellular matrix proteins
A few antigens in the extracellular matrix (ECM) have been
identified that are preferentially expressed in the surround-
ings of newly formed blood vessels, such as fibronectin,
laminin, tenascin and collagen type IV. A series of SPECT
tracers targeting the extra domain B of fibronectin for
imaging tumour angiogenesis have been developed
Extra domain B of fibronectin
Fibronectin is a large glycoprotein in the ECM. The extra
domain B (ED-B) of fibronectin is a sequence of 91 amino
acids, identical in mice, rats and humans, that is inserted
into the fibronectin molecule at sites of tissue remodelling
due to alternative splicing. ED-B is specifically expressed
around neovascular structures in tumours and other tissues
undergoing angiogenesis, but is undetectable in normal
adult tissues. Using phage display technology, single-chain
antibodies (scFv) directed against ED-B have been isolated.
The human single domain antibody (scFv) L19 was shown
to have subnanomolar affinity for ED-B [69].
Demartis et al. showed that radioiodinated scFv L19
selectively accumulated around tumoural blood vessels in a
murine tumour model. Since the ED-B domain of fibro-
nectin has an identical sequence in mouse and man, they
suggested clinical utility for the scintigraphic detection of
angiogenesis in vivo [70]. Two years later, it was shown by
scintigraphic imaging that
123I-L19 selectively localized in
tumour lesions of aggressive lung cancer as well as in liver
metastases of colorectal cancer patients [71]. More recently,
the amino acid sequence (Gly)3-Cys-Ala was inserted at the
C terminus of L19, resulting in the anti-ED-B scFv named
AP39, which could be labelled with
99mTc. The data
revealed the feasibility of targeting ED-B fibronectin with
99mTc-labelled L19 in nude mice with s.c. teratocarcinoma
tumours [72].
Subsequently a series of different L19 antibody formats
were constructed, including dimeric scFv, a human bivalent
“small immunoprotein” (SIP) and a complete human IgG.
In comparing these different formats labelled with
125I/
131I,
L19-SIP proved to be the most suitable tracer for imaging
ED-B expression in tumours.
Prostate-specific membrane antigen
Prostate-specific membrane antigen (PSMA) is a transmem-
brane protein which is overexpressed in prostate cancer. The
anti-PSMA antibody, capromab pendetide, labelled with
111In is marketed as ProstaScint®, an antibody preparation
approved by the US Food and Drug Administration (FDA)
for the detection of nodal metastases in prostate cancer
patients [73]. However, this antibody is directed against an
intracellular epitope of PSMA, which is considered a
suboptimal target for antibody imaging. PSMA was also
found to be expressed on the neovascular endothelium of
most solid tumour types, while there is no expression on
the endothelial cells of normal tissue [74].
J591 is a monoclonal antibody directed against an
epitope on the extracellular domain of PSMA [75].
Previous studies have shown that J591 accumulated in
metastatic prostate cancer lesions [76]. In a recent phase I
trial the feasibility of targeting the neovasculature of a wide
range of adenocarcinomas using
111In-labelled humanized
J591 was investigated. Patients with melanoma and cancers
of the breast, colon, liver and kidney received
111In-J591. In
these patients (n=24) the antibody accreted in all known
tumour sites. Of 18 patients with soft tissue disease on
standard scans, 17 (94%) showed uptake in the soft tissues
on antibody scans as did 6 of 6 patients with bone disease.
These data show selective targeting of PSMA expressed on
tumour endothelium [77].
111In-huJ591 has the potential to
become a suitable tracer for imaging angiogenesis.
Conclusions
In the last few years, significant progress has been made in
the development of SPECT tracers (peptides, proteins and
antibodies) for the non-invasive imaging of tumour angio-
genesis. These tracers might have the potential to select
patients who might benefit from treatment with antiangio-
genic drugs and these tracers might also be used to
therapeutic effect with these antiangiogenic drugs. Small
animal SPECT cameras have a higher resolution than
microPETcameras and in the clinical situation the difference
in resolution is marginal. PET isotopes are more expensive
than SPECT isotopes and single photon agents can provide
more specific targetingabilities thanPETagents,byenabling
dual-tracer imaging, which is still unique to SPECT.
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